Drug name - Balversa
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8895601 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
May, 2031
(8 years from now) | |
| CN102858765B | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitor |
Apr, 2031
(8 years from now) | |
| CN104725362B | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitor |
Apr, 2031
(8 years from now) | |
| CN104725362A | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitor |
Apr, 2031
(8 years from now) | |
| CN102858765A | JANSSEN BIOTECH | Pyrazolyl Quinazoline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| IN201202591P3 | JANSSEN BIOTECH | Pyrazolyl Quinazoline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| IN325020B | JANSSEN BIOTECH | A Process For The Preparation Of A Compound Of Formula (I) |
Apr, 2031
(8 years from now) | |
| EP3590934A1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP2563775B1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP3178818B1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP3590934B1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP3178818A1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP2563775A1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9464071 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2031
(8 years from now) | |
| US9902714 | JANSSEN BIOTECH | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(12 years from now) | |
| US10898482 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(13 years from now) | |
| US11077106 | JANSSEN BIOTECH | Cancer treatment |
Feb, 2038
(15 years from now) | |
Drugs and Companies using ERDAFITINIB ingredient
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 or fgfr2 genetic alterations, and progressed during or following prior platinum-containing chemotherapy, with dosing based on serum phosphate levels
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 3MG | TABLET;ORAL | Prescription |
| 4MG | TABLET;ORAL | Prescription |
| 5MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.